May 21, 2018 — The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission Computed Tomography (VECTor5) system to support its translational oncology mission, entrusted by the Italian Ministry of Health and the Organization of the European Cancer Institutes. Due to its high-resolution imaging capabilities, MILabs’ preclinical VECTor can enable a quick translation of molecular research from the bench to the clinic at the IOV.
According to Prof. Antonio Rosato, deputy scientific director and in charge of the preclinical imaging facility of the institute: “We anticipate that the unique ability of the MILabs system to image tumors with high-definition PET (positron emission tomography), SPECT (single-photon emission computed tomography) and CT modalities, further enhanced by high-resolution imaging of radiotherapeutic tracers such as 188Re, will accelerate IOV’s research on the personalization of therapy in solid tumors”.
By integrating multiple modalities on a single system, MILabs’ VECTor PET/SPECT/CT enables the expansion of diagnostic and treatment applications beyond the capabilities of any other preclinical imaging system, according to the company, including single-pass simultaneous PET and SPECT, dynamic molecular CT acquisitions, as well as theranostic imaging with alpha- and beta- radiotherapy nuclides.
For more information: www.milabs.com
April 25, 2024 
